Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zogenix Inc (ZGNX)

Zogenix Inc (ZGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,903,506
  • Shares Outstanding, K 44,247
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,910 K
  • 60-Month Beta 1.94
  • Price/Sales 1,778.98
  • Price/Cash Flow N/A
  • Price/Book 3.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.05
  • Number of Estimates 5
  • High Estimate -0.87
  • Low Estimate -1.19
  • Prior Year -0.93
  • Growth Rate Est. (year over year) -12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.45 +16.01%
on 10/02/19
44.89 -0.62%
on 10/17/19
+1.96 (+4.60%)
since 09/17/19
3-Month
38.45 +16.01%
on 10/02/19
52.14 -14.44%
on 08/23/19
-2.95 (-6.20%)
since 07/17/19
52-Week
33.43 +33.44%
on 12/24/18
56.50 -21.04%
on 03/29/19
+2.98 (+7.16%)
since 10/17/18

Most Recent Stories

More News
Bragar Eagel & Squire is Investigating Certain Officers and Directors of CBL & Associates Properties, EQT Corporation, and Zogenix and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of CBL & Associates Properties, Inc. (NYSE: CBL), EQT Corporation (NYSE: EQT), and Zogenix, Inc. (NASDAQ: ZGNX) on behalf of long-term...

CBL : 1.49 (+3.47%)
EQT : 9.95 (+4.08%)
ZGNX : 44.61 (+3.70%)
Zogenix Resubmits New Drug Application for FINTEPLA(R) for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application (NDA) for FINTEPLA(R) (ZX008, fenfluramine)...

ZGNX : 44.61 (+3.70%)
Relatively Good Performance Detected in Shares of Lannett Co Inc in the Pharmaceuticals Industry (LCI , ZGNX , AGN , HZNP , AERI )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

AGN : 172.50 (+0.92%)
LCI : 11.95 (+4.92%)
ZGNX : 44.61 (+3.70%)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ: ZGNX) for violations...

ZGNX : 44.61 (+3.70%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Orion Group Holdings, Zogenix, and Apyx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Orion Group Holdings, Inc. (NYSE: ORN), Zogenix, Inc. (NASDAQ: ZGNX), and Apyx Medical Corporation (NASDAQ: APYX) on behalf of long-term...

ORN : 4.28 (+3.63%)
ZGNX : 44.61 (+3.70%)
APYX : 6.90 (+5.34%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ: ZGNX) for violations...

ZGNX : 44.61 (+3.70%)
Zogenix Completes Acquisition of Modis Therapeutics, Inc.

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition of Modis Therapeutics, Inc., a privately-held...

ZGNX : 44.61 (+3.70%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ: ZGNX) for violations...

ZGNX : 44.61 (+3.70%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ: ZGNX) for violations...

ZGNX : 44.61 (+3.70%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ: ZGNX) for violations...

ZGNX : 44.61 (+3.70%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade ZGNX with:

Business Summary

Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome.

See More

Key Turning Points

2nd Resistance Point 46.04
1st Resistance Point 45.32
Last Price 44.61
1st Support Level 43.46
2nd Support Level 42.32

See More

52-Week High 56.50
Fibonacci 61.8% 47.69
Fibonacci 50% 44.97
Last Price 44.61
Fibonacci 38.2% 42.24
52-Week Low 33.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar